At Femtech Insider, we pride ourselves on our consistently growing event attendance. That's why last week's unusually low turnout for our briefing on autoimmune diseases and women's health caught my attention – and revealed something fascinating about our industry's blind spots.
The Hidden Giant in Women's Health
You might recall McKinsey's landmark report from earlier this year, which highlighted a striking statistic: while conditions that exclusively affect women account for just 3% of their disease burden, conditions that predominantly affect women drive a whopping 47% of their global disease burden. Autoimmune diseases fall squarely into this latter category.
Consider these eye-opening statistics from the CDC:
Perhaps the most startling revelation: autoimmune diseases represent the third most common disease category in the United States, following only cancer and heart disease. Yet they rarely command the same attention or investment.
Why the Silence?
Three key factors seem to be holding back innovation and investment in this space:
- Underestimated Opportunity: I believe that the market potential remains largely unrecognized despite the prevalence (see above)
- Complexity: Autoimmune conditions often involve intricate biological mechanisms and varied symptoms
- Investment Profile: Most activity centers around biotech, which carries higher risk profiles
Why You Should Pay Attention Now
I believe that the case for disruption in this space is compelling, starting with its sheer scale. As highlighted above, autoimmune diseases affect a massive population, with women bearing a disproportionate burden of these conditions.
Even more concerning is the growing prevalence we're observing. We're seeing a steady rise in autoimmune conditions, driven by a perfect storm of modern factors: changes in our dietary habits, increasing environmental pollution, greater exposure to chemicals, rising stress levels, and the emerging impacts of climate change. This confluence of factors makes the space not just important, but increasingly urgent.
The Timing Is Right
It seems we're at an inflection point where noise is beginning to transform into signal in the autoimmune-women's health intersection. And I expect we'll see significantly more coverage of innovations and entrepreneurs in this space.
If you missed our webinar, I strongly encourage you to watch the replay. While attendance was lower than usual, the content provides a great primer on this emerging opportunity in women's health.
Sometimes the most valuable insights come from the less crowded rooms. 🙂
